Our results described herein reveal the biological cellular program(s) and mechanism(s) underlying CD36-mediated anti-HER2 drug refractoriness and poor prognosis in this oncometabolic scenario, which were recently described in HER2 + BC in both preclinical and clinical settings [11, 13]. This evidence concerns the gene ERBB2 and breast cancer.